Genfit (Genfit) 3-Year Revenue Growth Rate : 206.30% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Genfit 3-Year Revenue Growth Rate?

Genfit's Revenue per Share for the three months ended in Dec. 2023 was $0.31.

During the past 12 months, Genfit's average Revenue per Share Growth Rate was 41.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 206.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was 138.60% per year. During the past 10 years, the average Revenue per Share Growth Rate was 37.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Genfit was 796.30% per year. The lowest was -61.50% per year. And the median was -27.35% per year.

Competitive Comparison of Genfit's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Genfit's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genfit's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genfit's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Genfit's 3-Year Revenue Growth Rate falls into.

Genfit 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Genfit (NAS:GNFT) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Genfit 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Genfit's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Genfit (Genfit) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genfit SA (NAS:GNFT) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

GNFTF:USA 0QT6:UK GNFT:France XUPB:Germany

Address

Parc Eurasante, 885, Avenue Eugene Avinee, Loos, FRA, 59120

Website

https://www.genfit.com

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. The company conducts clinical trials in a variety of European and North American countries when advancing through stages of development. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.